RANI Butterfly Strategy
RANI (Rani Therapeutics Holdings, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
RANI (Rani Therapeutics Holdings, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $68.6M, a beta of 0.76 versus the broader market, a 52-week range of 0.387-3.87, average daily share volume of 1.0M, a public-listing history dating back to 2021, approximately 105 full-time employees. These structural characteristics shape how RANI stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.76 places RANI roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a butterfly on RANI?
A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration.
Current RANI snapshot
As of May 15, 2026, spot at $1.10, ATM IV 203.00%, IV rank 42.74%, expected move 58.20%. The butterfly on RANI below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this butterfly structure on RANI specifically: RANI IV at 203.00% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 58.20% (roughly $0.64 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RANI expiries trade a higher absolute premium for lower per-day decay. Position sizing on RANI should anchor to the underlying notional of $1.10 per share and to the trader's directional view on RANI stock.
RANI butterfly setup
The RANI butterfly below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RANI near $1.10, the first option leg uses a $1.05 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RANI chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RANI shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.05 | N/A |
| Sell 2 | Call | $1.10 | N/A |
| Buy 1 | Call | $1.16 | N/A |
RANI butterfly risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit.
RANI butterfly payoff curve
Modeled P&L at expiration across a range of underlying prices for the butterfly on RANI. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use butterfly on RANI
Butterflies on RANI are pinning bets - traders use them when they expect RANI to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
RANI thesis for this butterfly
The market-implied 1-standard-deviation range for RANI extends from approximately $0.46 on the downside to $1.74 on the upside. A RANI long call butterfly is a pinning play: it pays maximum at the middle strike if RANI settles there at expiration, with the wing legs capping both the cost and the maximum loss to the net debit. Current RANI IV rank near 42.74% is mid-range against its 1-year distribution, so the IV signal is neutral; the butterfly thesis on RANI should anchor more to the directional view and the expected-move geometry. As a Healthcare name, RANI options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RANI-specific events.
RANI butterfly positions are structurally neutral / pin (limited-risk, limited-reward); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RANI positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RANI alongside the broader basket even when RANI-specific fundamentals are unchanged. Always rebuild the position from current RANI chain quotes before placing a trade.
Frequently asked questions
- What is a butterfly on RANI?
- A butterfly on RANI is the butterfly strategy applied to RANI (stock). The strategy is structurally neutral / pin (limited-risk, limited-reward): A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration. With RANI stock trading near $1.10, the strikes shown on this page are snapped to the nearest listed RANI chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are RANI butterfly max profit and max loss calculated?
- Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit. For the RANI butterfly priced from the end-of-day chain at a 30-day expiry (ATM IV 203.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a RANI butterfly?
- The breakeven for the RANI butterfly priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RANI market-implied 1-standard-deviation expected move is approximately 58.20%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a butterfly on RANI?
- Butterflies on RANI are pinning bets - traders use them when they expect RANI to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
- How does current RANI implied volatility affect this butterfly?
- RANI ATM IV is at 203.00% with IV rank near 42.74%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.